Design and Evaluation of Tumor-Specific Dendrimer Epigenetic Therapeutics

Histone deacetylase inhibitors (HDACi) are promising therapeutics for cancer. HDACi alter the epigenetic state of tumors and provide a unique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off-target effects have limited their use. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, Hong, Shah, Dhavan, Selwa, Katherine, Tsuchida, Ryan E, Rattan, Rahul, Mohan, Jay, Stein, Adam B, Otis, James B, Goonewardena, Sascha N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522184/
https://www.ncbi.nlm.nih.gov/pubmed/26246996
http://dx.doi.org/10.1002/open.201402141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522184/
https://www.ncbi.nlm.nih.gov/pubmed/26246996
http://dx.doi.org/10.1002/open.201402141

Ejemplares similares